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Background: This article describes the rationale and design of a population-based survey of dementia in Valladolid
(northwestern Spain). The main aim of the study was to assess the epidemiology of dementia and its subtypes.
Prevalence of anosognosia in dementia patients, nutritional status, diet characteristics, and determinants of
non-diagnosed dementia in the community were studied. The main sociodemographic, educational, and general
health status characteristics of the study population are described.
Methods: Cross-over and cohort, population-based study. A two-phase door-to-door study was performed. Both
urban and rural environments were included. In phase 1 (February 2009 – February 2010) 28 trained physicians
examined a population of 2,989 subjects (age: ≥ 65 years). The seven-minute screen neurocognitive battery was
used. In phase 2 (May 2009 – May 2010) 4 neurologists, 1 geriatrician, and 3 neuropsychologists confirmed the
diagnosis of dementia and subtype in patients screened positive by a structured neurological evaluation. Specific
instruments to assess anosognosia, the nutritional status and diet characteristics were used. Of the initial sample,
2,170 subjects were evaluated (57% female, mean age 76.5 ± 7.8, 5.2% institutionalized), whose characteristics are
described. 227 persons were excluded for various reasons. Among those eligible were 592 non-responders. The
attrition bias of non-responders was lower in rural areas. 241 screened positive (11.1%).
Discussion: The survey will explore some clinical, social and health related life-style variables of dementia. The
population size and the diversification of social and educational backgrounds will contribute to a better knowledge
of dementia in our environment.
Keywords: Dementia prevalence, Epidemiology, Undiagnosed dementia, Population-based survey, Seven-minute
screen, Anosognosia, Nutritional assessmentBackground
Demographic changes in world population during the
next decades will cause an appreciable increase in the
number of dementia patients [1]. Faced with the absence
of disease-modifying treatments, control of dementia
risk factors will be essential. A 10% reduction in dia-
betes, hypertension, obesity, smoking, depression, and
cognitive or physical inactivity could potentially prevent* Correspondence: mtola.nrl@gmail.com
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More studies are required of the prevalence and inci-
dence of dementia to chart the course of the disease, to
confirm a cautious optimism in epidemiological trends
[3], and to allow policymakers to plan the need for
services.
In recent years several dementia prevalence surveys
have been carried out in Spain [4-7] or are in progress
[8] with considerable geographic variation that may be
method-related [4]. A detailed analysis of the etiological
subtypes, beyond Alzheimer’s disease (AD) and vascular
dementia, has been generally lacking. To our knowledge,ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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memory clinics [9], has never been evaluated in popula-
tion studies. Other health related life style variables such
as nutrition or factors associated with the lack of or the
delay in the diagnosis of the disease in the community
[10,11] have barely been analyzed and thus justify new
research in this field.
In 2008 we initiated the Dementia in Valladolid
(DEMINVALL) survey in two geographically well-
defined urban and rural populations in northwestern
Spain aimed at describing (1) the prevalence and inci-
dence of dementia and its subtypes, (2) the prevalence of
anosognosia in dementia patients, (3) the characteristics
of undiagnosed dementia in the community, and (4) the
nutritional status and the daily consumption of micro
and macronutrients. In this report we describe the de-
sign, methodology, and main general health, educational,
and sociodemographic features of the study population.
Methods/Design
Geographical area
In January 2009, the population of the province of
Valladolid was 532,575 (18.2% ≥ 65 years) with 6.7% of
institutionalized persons. The city of Valladolid (189
Km northwest of Madrid) has a population of 317,864,
which has remained stable during last 10 years [12].
The main economic activities are manufacturing and
service sector in urban areas and agriculture and
viticulture in rural ones. Health care in Valladolid is
organized into two separate areas, each with a univer-
sity hospital that includes a neurology department and
a geriatrics unit. Primary care is provided at communityR
Madrid
Valladolid province  
Figure 1 Location of the province of Valladolid and the rural area (m
Castrodeza, Torrelobatón, Matilla de los Caños, Robladillo, Villán de Thealth centers and in doctors’ offices in small rural
areas.
Study population
The participants were sampled from the primary care
registry of Social Security health card holders. In Spain,
health care is free and universal, covering virtually the
entire population. This selection method has various
advantages: (1) it is continually updated; (2) provides
personal data such as address, phone number and pri-
mary care physician; (3) provides access to medical rec-
ord; (4) improved external validity.
In order to obtain a sample of all educational back-
grounds and social classes in Valladolid, in addition to a
good diversification of dementia risk factors, a mixed
population -urban and rural- was selected. Community-
dwelling and nursing home residents were included.
Rural residential environment
We selected the whole population aged 65 years and over
of 11 municipalities of the “Montes Torozos” region (870
residents) in northwestern Valladolid (338.9 Km2, popu-
lation density 12.6/km2). In this rural area (Figure 1),
primary care is available in two community health cen-
ters. The population is mainly blue-collar workers.
Urban residential environment
Residents aged 65 years and over from the districts of
Campo Grande and Parquesol of the city of Valladolid
(6,183 individuals) were selected. Each of these districts
has a community health center. Due to the large popula-
tion size, the survey was based on a 34.2%, random, 5-Valladolid city
ural area 
.
Urban area
unicipalities of Villanubla, Peñaflor de Hornija, Wamba, Ciguñuela,
ordesillas, Velilla and Velliza).
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individuals. The size was calculated in order to provide
an estimated 6.5% prevalence, 1% precision, 95% confi-
dence interval, and 20% predicted losses. Both white and
blue-collar workers are represented in this sample.
The eligibility criteria for this mixed population of
2,989 subjects were age 65 years and over on 1 February
2009 and at least 6 months residence in the previous
year in the selected geographic areas. These areas were
chosen for the following reasons: (1) existence of a com-
puterized registry of the medical diagnoses of the partici-
pants; (2) the Rio Hortega University Hospital (RHUH)
is the reference centre for the neurological and geriatric
evaluation for both areas, with a single neurological
team and a geriatrics unit; (3) a close relationship be-
tween the researchers and the primary care physicians;
(4) proximity of the rural area to the RHUH.
Study design
DEMINVALL is a cross-over and cohort, population-based
study. A cross-sectional, two-phase door-to-door design
was adopted. Point prevalence was used as a disease fre-
quency measure. The prevalence date was 1 February
2009. In order to be included in the prevalence numerator
the patients had to be alive and had to meet the diagnostic
criteria for dementia on or before this date.
The patients detected in the prevalence study have
been followed up at regular intervals in the out-patient
clinics of neurology and geriatrics in the RHUH. A
dementia-free cohort was generated. The survivors of
this cohort will be re-evaluated between October 2012
and May 2013 to describe the incidence of dementia and
subtypes following a minimum observation period of
three years from the prevalence date. A similar method-
ology will be used in two phases.
Phase 1: screening
In October 2008, a meeting of the researchers was held
in which different clinical and epidemiological aspects of
dementia were reviewed. Prior to the beginning of the
survey a letter was sent to all selected subjects inviting
them to participate and stating the absence of risk. In
addition, the study was announced on the local radio,
television, and press, and posters were placed in the
health centers in order to better publicize the study.
Field work team
The participants were evaluated by 27 primary care phy-
sicians and one geriatrician from the largest nursing
home. Five of the physicians coordinated the field work.
All were trained to standardize the answers and to inter-
pret the screening instruments. Whenever possible, the
evaluation was carried out by the regular physicians.Screening protocol
The initial interview was arranged by telephone and was
held in the community health centers, physician’s offices,
or when necessary, in the participant’s home or nursing
home. At least five attempts to locate a potential partici-
pant within a period of three months were required in
order to classify a subject as a non-located. Participants
were asked to provide their medical reports and medica-
tions. Available medical records were also reviewed. The
duration of the evaluation was 30 minutes and, when ne-
cessary, it was carried out in the presence of reliable
informants. The evaluation period of the first phase was
from February 2009 to February 2010.
Before administering the screening test, the eligibility
criteria were confirmed and a structured questionnaire
was filled out. Data concerning marital status, cohabit-
ation, educational level and occupation history were col-
lected. Social status was calculated according to an
algorithm based on profession and level of training [13].
If a previous diagnosis of dementia existed, the type,
onset date, main initial symptom, and date and level of
care of diagnosis were evaluated. All those patients pre-
viously diagnosed with dementia were evaluated in the
second phase of the study, regardless of whether or not
the screening test results were negative or positive. In
the absence of this diagnosis, existence of prior consulta-
tions for cognitive impairment, complaint symptoms
and level of care in which they were held were evaluated.
Also, information relative to the subjective health status,
family history of dementia, cranial trauma, thyroid dis-
ease, and depression was collected. History of Parkin-
son’s disease, essential tremor, stroke, ischemic heart
disease, hypertension, and diabetes were evaluated. Dur-
ation of the illness, medications, and degree of control
were specified. A history of tobacco and alcohol con-
sumption (standard units of alcohol intake per week)
was taken [14]. In addition, physical activity during the
previous year was stratified according to intensity and to
the number of days of exercise per week [15]. The blood
pressure of those subjects without a history of hyperten-
sion was measured on two separate occasions. Finally,
the body mass index was calculated.
Screening instruments
The 7 Minute Screen Neurocognitive Battery (7MS)
was used [16]. This instrument evaluates temporal
orientation, naming, delayed free- and cued-recall test
of memory impairment, visuospatial organization, se-
mantic processing and storage. A score of <20 points
(8 percentile), regardless of age and cultural level, was
considered positive. When it was not possible to per-
form the 7MS, the reasons were given and the short
version of the Informant Questionnaire on Cognitive
Decline in the Elderly (IQCODE) [17] was employed.
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case of death after the prevalence date, collaboration
of a close relative was sought, medical and sociocul-
tural data were collected, and a Spanish version of the
Kawas Dementia Questionnaire [18] was employed.
This instrument provides a structured review of the
general diagnostic criteria of dementia, AD, vascular
dementia, and secondary dementia.
Phase 2: Diagnostic confirmation
Clinical research team
The neurological assessment was carried out by four
neurologists and one geriatrician, all experienced in de-
mentia evaluation. Three neuropsychologists performed
the neuropsychological evaluation. The coordinators of
the first phase carried out the nutritional assessment,
aided by the research unit of the RHUH and by a diet-
ician. Two social workers conducted the social evalu-
ation by telephone. A nurse took blood samples in the
homes of those participants unable to travel. Genomic
DNA was extracted from whole-blood samples and
amplified by using polymerase chain reaction in the
genetic department of the RHUH to determine ApoE
genotype.
Assessment protocol
A comprehensive neurological assessment was offered to
those participants with a positive screen or previous
diagnosis of dementia. In addition, a randomly selected
control group of 160 subjects was included (8.3% of
those who screened negative). The proportions of sex
and age stratification with regard to those who screened
positive were respected. The assessment was carried out
in the out-patient clinics of neurology, geriatrics, and
clinical psychology in the RHUH during two or three
visits in the presence of a reliable informant. It was per-
formed in the subject’s home when necessary. The evalu-
ation period was from May 2009 to May 2010. After
revising the medical record and medications, a struc-
tured neurological examination was performed.
A brain imaging test (cranial CT or 1.5 T MRI) was
suggested for all the subjects who screened positive. A
single photon emission computed tomography imaging
using [123] FP-CIT (DaTSCAN; GE Healthcare) was car-
ried out on some patients with dementia and parkinson-
ism. Complete blood count, biochemical analysis, lipids,
vitamin B12 levels, thyroid function, luetic serology,
homocysteine, albumin, prealbumin, transferrin, and
ApoE genotype were analyzed.
The neuropsychologic evaluation consisted of the use
of the Cambridge Examination of Mental Disorders of
the Elderly (CAMDEX) [19]. This instrument includes
the necessary information to diagnose dementia and its
subtypes, and includes an interview with an informant,the Blessed Scale, and an ischemic and depression scales.
It also includes the Cambridge Cognitive Examination
(CAMCOG) [20] that permits the scoring of the Mini-
Mental State Examination (MMSE).
In addition, the protocol included the following instru-
ments: (1) Rapid Disability Rating Scale-2 [21]; (2) Pitts-
burgh Sleep Quality Index [22]; (3) Zarit scale for
assessing caregiver burden [23]; (4) Clinical Dementia
Rating (CDR) [24]; (5) Global Deterioration Scale for as-
sessment of primary degenerative dementia (GDS) [25],
and (6) Functional Assessment Staging (FAST) [26]. In
order to evaluate anosognosia, the Clinical Insight Rat-
ing Scale [27] and the Rating of Awareness Deficit [28],
which were previously validated, were applied. The con-
sumption of healthcare resources during the previous
year was quantified by employing a questionnaire based
on a national health survey of the Spanish National In-
stitute of Statistics [29]. For the social evaluation, a
structured interview of widespread use in Spain was
employed [30].
For the nutritional evaluation, the Mini Nutritional
Assessment Test was used [31]. In addition, a nutritional
questionnaire was carried out in order to calculate the
daily consumption of macro and micronutrients. To this
end subjects were given a form in which they registered
their consumption during a two-day period, one of the
days falling on a weekend. The dietary data was mana-
ged by means of a personal computer, and the use of
food scales and models to enhance portion size accuracy
were incorporated. Records were reviewed by a regis-
tered dietitian and analyzed with a computer-based data
evaluation system. National composition food tables
were used as a reference [32].
Diagnostic criteria
Clinical diagnosis of dementia was established by
agreement between the neurologist or geriatrician and
the neuropsychologist responsible for each individual
evaluation. Problematic cases and all the dementia
questionnaires were reviewed by a second neurologist
(M.A.T-A.).
The criteria of the Diagnostic and Statistical Manual
of Mental Disorders (DSM-IV) [33] were applied for the
diagnosis of dementia syndrome. In addition, the criteria
of NINCDS-ADRDA for AD [34], the criteria of
NINDS-AIREN for vascular dementia [35], the criteria
of the DLB Consortium for dementia with Lewy bodies
[36], the criteria for dementia associated with Parkin-
son’s disease [37], and the criteria for frontotemporal
lobar degeneration were applied [38]. AD with cerebro-
vascular disease was regarded as present in those
patients that met the criteria of NINCDS-ADRDA for
possible AD and who presented significant levels of
small vessel ischemic changes, strategic lacunar infarcts,
Population sample of health card 
holders on 1 November 2008
n = 2,989
Eligible population sample
n = 2,762 
Excluded (n = 227)
Deaths 57
Address changes 102
Nonresidents 68 
Refusals 412
Not located 180 
Study population 
On 1 February 2009
n = 2,170
Screened positive
n = 241
Clinically evaluated
n = 212
Phase 1
Phase 2
Figure 2 Flow chart showing the population selected and finally evaluated.
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who had a history of stroke or impaired neurological
examination (focal deficit or gait disturbances) [39]. Sec-
ondary dementia was classified as having an identifiable
or probable cause. When the clinical information was in-
sufficient to reach an etiologic classification, undeter-
mined dementia was diagnosed.Table 1 Distribution of the evaluated population stratified by
Age, years Urban population (n = 1,459) Rural
Men, n Women, n Men,
65–69 162 (27.7%) 213 (24.4%) 91 (26.
70–74 154 (26.3%) 177 (20.3%) 84 (24.
75–79 124 (21.2%) 160 (18.3%) 79 (22.
80–84 83 (14.2%) 152 (17.4%) 61 (17.
85–89 42 (7.2%) 111 (12.7%) 26 (7.5
≥90 20 (3.4%) 61 (7.0%) 7 (2.0
Total 585 (100%) 874 (100%) 348 (10
All percentages are column percentages.Ethical aspects
The survey was approved by the Ethics and Clinical Re-
search Committee of the RHUH. All participants (or a
relative when necessary) were asked to sign an informed
consent. The database was inscribed in the Spanish
Agency for Data Protection. Treatment and follow-up
were offered to all patients with undetected dementia.age, sex, and living environment
population (n = 711) Total population (n = 2,170)
n Women, n Men, n Women, n
1%) 83 (22.9%) 253 (27.1%) 296 (23.9%)
1%) 60 (16.5%) 238 (25.5%) 237 (19.2%)
7%) 86 (23.7%) 203 (21.8%) 246 (19.9%)
5%) 68 (18.7%) 144 (15.4%) 220 (17.8%)
%) 40 (11.0%) 68 (7.3%) 151 (12.2%)
%) 26 (7.2%) 27 (2.9%) 87 (7.0%)
0%) 363 (100%) 933 (100%) 1,237 (100%)
Table 2 Differences among analyzed and non-located
subjects and refusals
Analyzed Non-located Refusals
n = 2,170 n = 180 n = 412
Age (Mean ± SD), years 76.5 ± 7.8 76.6 ± 7.8 76.4 ± 7.9
Women (%) 57% 55% 61.2%
Institutionalized (%) 5.2% 2.2% 3.2%
Rural area (%) 32.8% 16.7%1 14.6%2
Age, years
65–69 25.3% 28.9% 27.4%
70–74 21.8% 18.3% 19.2%
75–79 20.7% 16.7% 22.1%
80–84 16.8% 22.2% 16.0%
85–89 10.1% 8.9% 9.5%
≥90 5.3% 5.0% 5.8%
1 p < 0.001. Difference between non-located and analyzed subjects.
2 p < 0.001. Difference between refusals and analyzed subjects.
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reported to the primary care physicians.Results
Figure 2 shows a flow chart of participant attrition. 227
subjects (7.6%) were excluded from the initial population
for different reasons. Of the 2,762 eligible subjects, 180
(6.5%) were non-located and 412 (14.9%) refused to par-
ticipate. The final population evaluated in the first phase
was composed of 2,170 individuals; 241 (11.1%) screened
positive. Table 1 shows the distribution of the final
population by age, sex and area of residence. Table 2 dis-
plays the differences between this population, non-
located and non-collaborators. A smaller proportion of
non-responders in rural areas was statistically significant.
We obtained information about the educational level of
2,115 participants (97.5%). Table 3 shows the distribu-
tion by age and gender. The sociodemographic data, oc-
cupation, general health, vascular risk factors and habits
are displayed in Table 4, including the number of sub-
jects analyzed in each case.Table 3 Educational level of DEMINVALL participants by age
Age, years Illiterate(n = 25) Less than primary school (n = 451)
Men Women Men Women
65–69 2 2 41 49
70–74 0 2 31 43
75–79 1 6 46 64
80–84 1 6 39 59
85–89 1 3 13 40
≥90 0 1 6 20
Total 5 20 176 275
Total years of schooling: 9.0 ± 4.1.Discussion
From a methodological point of view, the DEMINVALL
study presents some interesting differential characteris-
tics with respect to other similar studies undertaken dur-
ing the past few years [4-8]. First of all, the entire
process of screening of the participants was carried out
by trained medical personnel. In many cases this evalu-
ation was performed by the subjects’ habitual physicians.
This fact contributed to a good participation in the
urban area and to an optimum participation in the rural
one. A similar approach was employed in the NEDISA
[8] survey in Salamanca, Spain, in which a participation
result of over 95% was obtained.
A second differential aspect is the choice of the
screening instrument. In the majority of the population-
based surveys local versions of the MMSE have been
employed [40]. The limitations of this test are well
known, especially with regard to sensitivity and low posi-
tive predictive value in individuals with a low cultural
level [41]. The 7MS was originally proposed as a screen-
ing test for AD, although it usefulness in other types of
dementias has been demonstrated [42]. Sensitivity and
specificity of the 7MS are high and normative data con-
cerning the Spanish population are available [43]. Due to
its higher performance in the evaluation of episodic
memory, it can contribute to the reduction of cost of
screening in population studies, since it optimizes the
detection of AD [44]. The main limitations are the ad-
ministration time, which is normally over ten minutes,
the requirement that the subject make a drawing of a
clock, which limits its administration in patients with
serious physical or sensorial defects, and the calculation
of the score. Its usefulness has been placed in doubt in
large epidemiological studies for these reasons [45]. Our
initial hypothesis was that, despite these limitations, its
greater efficacy allowed us to carry out a more reliable
screening and, above all, a more efficient one (only
11.1% of the evaluated subjects were screened positive)
with a lower consumption of healthcare resources in the
second phase. The analysis of the false negatives in the
control group and its positive predictive value willgroups and gender
Primary school(n = 1,092) Secondary school and higher (n = 547)
Men Women Men Women
104 165 104 79
129 139 78 47
93 124 61 47
69 107 28 41
37 73 13 28
11 41 6 15
443 649 290 257
Table 4 Characteristics of the evaluated population
Sociodemographic
Marital Status,% (n = 2,122)
Single 11.3
Married 60.1
Widowed 27
Separated/divorced 1.6
Living arrangements,% (n = 2,170)
Alone 18.1
With spouse 45.7
With relatives 26.6
Institutionalized 5.2
Others (including rotation among relatives) 4.4
Social class,% (n = 2,121)
Low 16.4
Medium-low 52.5
Medium 22.3
Medium-high 7.9
High 0.9
Occupation/employment
Work history,% (n = 2,121)
Blue-collar 67.2
White-collar 18.3
Services 12.7
Never employed 1.8
Current occupation,% (n = 2,116)
Retired with no activity 54.7
Active in habitual profession 36.7
Housewife/husband 8.6
General data concerning health and habits
Subjective state of health,% (n = 2,067)
Bad or very bad 7.4
Average 29.1
Good or very good 63.5
Body mass index (n = 2,029) 27.3 ± 4.2
Vascular risk factors,% (n =2,170)
Diabetes mellitus 15.8
Hypertension 55.7
Ischemic heart disease 10.7
Stroke 6.3
Ever-smoker 38.2
Alcohol consumption,% (n = 2,124)
Never drinker 57.8
Active drinker 34.7
Ex –drinker 7.5
Daily consumption of alcohol (gr ethanol) 15.8 ± 1.5
Active drinkers at risk1 7.32
Physical exercise,% (n = 2,170)
Sedentary 18.1
Table 4 Characteristics of the evaluated population
(Continued)
Low activity 21.6
Moderate activity 47.4
High activity 12.9
1 Daily consumption of ethanol over 30 gr.
2 Percentage of active drinkers.
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In any case, the protocol established the application of
the IQCODE, with a sensitivity similar to that of the
MMSE [46], in those cases in which the application of
the 7MS was not possible.
The survey included a specific evaluation of the char-
acteristics of undiagnosed dementia in the community
with the purpose of explaining the determinants of the
delay or lack of identification of the disease in our envir-
onment. Among these, we analyzed the loss of insight,
quite frequent in dementia, although it has never been
evaluated in population-based studies. Finally, the nutri-
tional evaluation of subjects with confirmed dementia
and their comparison with the control group will pro-
vide valuable data concerning the influence of diet on
dementia and of the latter on the nutritional state of
the patients. In this sense, a favorable effect of the
Mediterranean diet typical to our environment has been
demonstrated [47].
A major limitation of the DEMINVALL survey, as in
the majority of the observational studies with large
populations, is the sample attrition bias. From the initial
population, 7.6% of the selected subjects were excluded
because they did not comply with the eligibility criteria,
in part due to outdated health cards. Among the eligible
subjects 21% were excluded from the denominator for
the prevalence calculation because they were non-
responders. In the analysis of differences among the
evaluated subjects and non-responders, only a lower par-
ticipation in the urban area was statistically significant.
The sample size of the latter, it should be pointed out,
was calculated based on a predicted 20% loss; therefore,
the impact bias will be lower.
In summary, we have presented the design and meth-
odology of the DEMINVALL survey. It will allow us a
more accurate view of the frequency of dementia in our
environment and the reasons for diagnosis delay or the
lack of detection. Therefore, we can contribute to a
more efficient planning of health and social resources
and to the implementation of plans that will facilitate
early diagnosis, an aspect of maximum importance in
the moment in which modifying treatments of the dis-
ease are available.
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